Gypenoside XLIX and Mitochondria-Associated ER Membranes in Non-Alcoholic Fatty Liver Disease: Mechanistic Insights and Emerging Perspectives
Molecules · 17.04.2026 · 31 (8) · 1325
DOI: 10.3390/molecules31081325 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 17.04.2026. Verfasst von Xinyi Kwan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Traditional Chinese Medicine, School of Medicine, Xiamen University, Xiamen 361102, China. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Mitochondria, Endoplasmic Reticulum, Saponins. Die Arbeit nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Traditional Chinese Medicine Foundation of Xiamen, Xiamen University Malaysia Fund, National Natural Science Foundation of China.
Abstract (Originalsprache)
Gypenoside XLIX is a bioactive saponin with reported diverse biological activities, including antioxidant, regulation of cell growth, immune responses, and metabolic regulatory properties. The increasing global prevalence of non-alcoholic fatty liver disease (NAFLD) underscores the importance of exploring novel therapeutic agents such as Gypenoside XLIX. NAFLD pathogenesis involves lipotoxicity, oxidative stress, and mitochondrial dysfunction, in which mitochondria-associated endoplasmic reticulum membranes (MAMs) play a critical role in organelle communication, calcium signaling, and lipid metabolism. This narrative review summarizes current evidence indicating that Gypenoside XLIX may modulate oxidative stress, restore mitochondrial membrane potential, and regulate calcium homeostasis, thereby indirectly influencing MAM integrity and function. These effects can reduce lipid accumulation, improve hepatocellular metabolism, and attenuate inflammatory responses. This review evaluates the mechanistic impact and function of Gypenoside XLIX on MAM integrity and its effects on NAFLD. However, there is limited direct experimental evidence linking Gypenoside XLIX to MAM regulation, and further studies are required to validate its mechanisms and therapeutic potential in clinical settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Traditional Chinese Medicine, School of Medicine, Xiamen University, Xiamen 361102, China.
- School of Traditional Chinese Medicine, Xiamen University Malaysia, Sepang 43900, Malaysia.
- Hepatology Unit, Xiamen Hospital of Traditional Chinese Medicine, Xiamen 361009, China.
ORCID-Profile: Xinyi Kwan, Muhammad Shahzad Aslam, Shaodong Chen
Förderung
- Traditional Chinese Medicine Foundation of Xiamen
- Xiamen University Malaysia Fund
- National Natural Science Foundation of China
- Fujian Provincial Natural Science Foundation
- Xiamen Municipal Science and Technology Plan Project
- Xiamen Municipal Traditional Chinese Medicine Support Project
- Fujian Provincial Key Science and Technology Project of Traditional Chinese Medicine
Zitieren
APA
Kwan, X., Aslam, M. S., Liang, H., & Chen, S. (2026). Gypenoside XLIX and Mitochondria-Associated ER Membranes in Non-Alcoholic Fatty Liver Disease: Mechanistic Insights and Emerging Perspectives. Molecules, 31(8), 1325. https://doi.org/10.3390/molecules31081325
Vancouver
Kwan X, Aslam MS, Liang H, Chen S. Gypenoside XLIX and Mitochondria-Associated ER Membranes in Non-Alcoholic Fatty Liver Disease: Mechanistic Insights and Emerging Perspectives. Molecules. 2026;31(8):1325. doi:10.3390/molecules31081325
BibTeX
@article{Kwan2026,
author = {Kwan, Xinyi and Aslam, Muhammad Shahzad and Liang, Huiqing and Chen, Shaodong},
title = {Gypenoside XLIX and Mitochondria-Associated ER Membranes in Non-Alcoholic Fatty Liver Disease: Mechanistic Insights and Emerging Perspectives},
journal = {Molecules},
year = {2026},
volume = {31},
number = {8},
pages = {1325},
doi = {10.3390/molecules31081325}
}
EUVIMED